Welcome to our dedicated page for Enzon Pharma SEC filings (Ticker: ENZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enzon Pharmaceuticals, Inc. (ENZN) files a range of documents with the U.S. Securities and Exchange Commission that are central to understanding its role as a public company acquisition vehicle and its proposed merger with Viskase Companies, Inc. On this page, you can review Enzon’s Form 8-K current reports, which detail material events such as the execution of the Agreement and Plan of Merger, subsequent amendments to that agreement, and changes to its Section 382 Rights Agreement.
Merger-related 8-K filings describe the structure of the all-stock transaction in which Viskase will merge with and into a wholly owned Enzon subsidiary, the exchange ratios between Viskase common stock, Enzon common stock, and Enzon’s Series C Non-Convertible Redeemable Preferred Stock, and the anticipated post-merger ownership split, including the expectation that current Viskase stockholders will own 55% of the combined company following the amended merger terms. These filings also outline requirements such as a 1-for-100 reverse stock split of Enzon common stock and the role of Icahn Enterprises Holdings L.P. and its affiliates under a support agreement.
Other key filings relate to Enzon’s Section 382 Rights Agreement. Through multiple amendments reported on Form 8-K, Enzon has adjusted the Final Expiration Date of the rights issued under this agreement. The company notes that these amendments are intended to revise the expiration date while leaving the rest of the agreement unchanged, and that management believes the revised dates are in the best interests of stockholders.
Enzon has also stated that it intends to file a registration statement on Form S-4 in connection with the Viskase merger. That filing is expected to contain a consent solicitation statement and prospectus and to include financial information about the combined company. On this page, AI-powered tools can help summarize lengthy filings, highlight key transaction terms, and make it easier to understand complex documents such as merger agreements, rights agreements, and related exhibits.
Viskase Holdings, Inc. filed an initial insider ownership report for company officer Robert Schouten. The Form 3 identifies him as an officer (title noted as “See Remarks”) but shows no reported transactions or derivative positions and does not list any specific share holdings in this data.
Viskase Holdings, Inc. officer Stender Mackenzie has filed an initial statement of beneficial ownership as a company insider. This filing lists Mackenzie as an officer but shows no reported share purchases, sales, or other transactions, and no derivative positions in the data provided.
Viskase Holdings, Inc. insider John Plescia filed an initial ownership report on Form 3. He is identified as an officer of the company, with his specific officer title referenced in the remarks section. The filing reports no transactions or current derivative holdings.
Viskase Holdings, Inc. director Peter Shea has filed an initial Form 3, which is a required statement of beneficial ownership for company insiders. The provided data shows no reportable transactions or derivative positions and does not list any specific shareholdings for this reporting person.
Viskase Holdings, Inc. director Colin Nicholas Kwak filed an initial Form 3, which is the required statement of beneficial ownership for insiders. The filing identifies him as a director of the company and does not report any insider transactions in the provided data.
Viskase Holdings, Inc., formerly Enzon Pharmaceuticals, completed its all-stock merger with Viskase Companies, Inc., making Viskase a wholly owned subsidiary that has been converted into Viskase Companies, LLC. The combined company will focus on Viskase’s meat and poultry casing business.
Enzon stockholders immediately before the merger own approximately 45% of the combined company’s common stock, while former Viskase stockholders own about 55%. Each share of Viskase common stock was converted into the right to receive 0.049118 shares of company common stock.
Before closing, 39,277 shares of Series C Preferred Stock held by Icahn Enterprises affiliates were exchanged into 5,658,396 common shares. The company changed its name to Viskase Holdings, Inc., eliminated its Series A-1 Junior Participating Preferred Stock designation, and its common stock is trading on the OTCQB under temporary symbol ENZND for 20 trading days.
Enzon Pharmaceuticals, Inc. issued a press release announcing the completion of the exchange offer relating to its Series C Non-Convertible Redeemable Preferred Stock on March 25, 2026. The press release is attached as Exhibit 99.1 and incorporated by reference; the exhibit is not being "filed" for purposes of Section 18 of the Exchange Act.
Enzon Pharmaceuticals, Inc. reported that it has completed the exchange offer relating to its Series C Non-Convertible Redeemable Preferred Stock. The company disclosed this by issuing a press release, which is included as an exhibit to the report and incorporated by reference.
The information and attached press release are being furnished rather than filed, meaning they are not subject to certain liability provisions under the Exchange Act or automatically incorporated into other securities law filings unless specifically referenced.
Enzon Pharmaceuticals, Inc. reports the final results of its exchange offer to holders of Series C Non-Convertible Redeemable Preferred Stock. The offer expired at 5:00 p.m., Eastern Time, on March 24, 2026. The depositary reported 339 shares were validly tendered and not withdrawn, representing less than 1% of the 40,000 Series C shares outstanding as of March 24, 2026. Enzon accepted for exchange all validly tendered shares and will exchange them in accordance with the offer terms. A press release dated March 25, 2026 announcing results is attached as an exhibit.
Enzon Pharmaceuticals, Inc. amends its Schedule TO to report developments in the exchange offer to convert Series C Non-Convertible Redeemable Preferred Stock into shares of Common Stock. The amendment states the Reverse Stock Split became effective on March 24, 2026 at 4:30 p.m. Eastern Time and that Common Stock is expected to trade on a reverse-split adjusted basis on the OTCQB at market open on March 25, 2026. The company states the Reverse Stock Split was required prior to the consummation of the Merger. All other Offer terms and disclosures are incorporated by reference to the Prospectus/Consent Solicitation/Offer to Exchange.